Appareil pulmonaire BP40657 A TWO-PART PHASE Ib/II STUDY TO INVESTIGATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF ATEZOLIZUMAB SUBCUTANEOUS IN PATIENTS WITH STAGE IV;NONÀSMALL CELL LUNG CANCER Paris
Sein métastatique HER2+ DS8201-A-U301 (DESTINY- Breast02) A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1. Paris, Saint-Cloud
Sein métastatique HER2+ DS8201-A-U302 (DESTINY-Breast03) A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane Paris, Saint-Cloud
Appareil pulmonaire ENTREE-LUNG (GSK 205801) A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants Paris NICOLAS GIRARD
Appareil pulmonaire LUMINOSITY (M14-239) Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Phases précoces tumeurs solides MK4621-002 A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors Paris
Phases précoces tumeurs solides M16-074 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors. Paris
Sein métastatique HER2+ PATINA A Phase III, Randomized, Open Label Trial to Evaluate the Efficiency and Safety of Palbociclib + AntiHER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Reception Positive (HR+)/HER2 Positive Metastatic Breast Cancer MBC-1 Paris, Saint-Cloud
Appareil pulmonaire EDI-1001 Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer Paris NICOLAS GIRARD
Phases précoces tumeurs solides ARROW (BLU-667-1101) A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Paris NICOLAS GIRARD